Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

S. Rugo, Hope; S. Finn, Richard; Dièras, Véronique; Ettl, Johannes; Lipatov, Oleg; A. Joy, Anil; Harbeck, Nadia; Castrellon, Aurelio; Iyer, Shrividya; R. Lu, Dongrui; Mori, A.; Gauthier, Eric; Huang Bartlett, Cynthia; A. Gelmon, Karen; J. Slamon, Dennis

doi:10.1007/s10549-018-05125-4

Public

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Published in Breast Cancer Research and Treatment • Jan 10, 2019

Authors:

Hope S. Rugo

Richard S. Finn

Véronique Dièras

Abstract

PURPOSE: In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast canc...

Subject

Palbociclib

Letrozole

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!